69 results about "Cefamandole nafate" patented technology

The invention relates to a synthetic method of the antibiotic cefamandole nafate, which adopts the 7-amino-3-(1-methyl-1H-tetrazoline-5-base)-sulfomethyl-3-cef-4-carboxylic acid as raw material and gains the solid of the cefamandole nafate through such five steps as the silylation reaction, acylation reaction, hydrolysis reaction, decolorization and salifying. The silanizing agent used in the silylation reaction adopts the mixture of the silicon amine alkane and the alkylogen silane. Compared with the prior art, the invention is characterized by simple in process operation, low in cost, high in product yield, good in product quality and suitable for industrial production.

The invention relates to an aseptic powder injection of cefamandole nafate and a preparation method thereof; the aseptic powder injection of cefamandole nafate comprises cefamandole nafate and anhydrous sodium carbonate; after the improvement of the preparation technology, the dosages of auxiliary material are small, and therefore the aseptic powder injection of cefamandole nafate obtained is good in stability and low in cost. The synthetic process of the drug material of cefamandole nafate adopted by the invention has simple operation process, low material cost and moderate reaction conditions; the cefamandole nafate produced has high purity and high productive rate.

The invention relates to a cefamandole nafate hydrate. The molecular formula of the cefamandole nafate hydrate is C19H17N6NaO6S25H2O. The preparation method of the cefamandole nafate hydrate comprises the following steps of: dissolving cefamandole nafate crude drug in water and placing the dissolved cefamandole nafate crude drug in a crystallizer; adding 5-15 parts of elution agents, cooling the mixture to 2-8 DEG C, separating out solids and then filtering; and rinsing the solids in the elution agents, drying for 3-5 hours at the drying temperature of 10-50 DEG C under a ventilated or vacuumcondition to obtain the cefamandole nafate hydrate. The invention also provides a cefamandole nafate for injection, which is prepared by using the cefamandole nafate hydrate as the crude drug. The cefamandole nafate hydrate obtained in the method has the advantages of smooth surface, good stability and high dissolving sped in water. After the cefamandole nafate hydrate is dissolved in the water, the action mechanism and the clinical effect of the cefamandole nafate hydrate are the same as those of cefamandole nafate prepared in the traditional process.

Disclosed is a method to separate and purify cefamandole nafate, which is characterized in that cefamandole nafate is separated and purified for three times through a high-speed countercurrent chromatograph which adopts a solvent system composed of trichloromethane, ethyl acetate, carbinol and water, with the upper phase being stationary and the lower phase being mobile. The cefamandole nafate can be further froze and dried to prepare freeze-dried powder injection. The method greatly increases the purity of the material up to 99%, and the purification process causes no pollution; therefore the method is good for industrial continuous production.

The invention relates to a cefamandole nafate compound and a pharmaceutical composition of the cefamandole nafate compound. The cefamandole nafate compound is crystal, and is determined by X-ray powder diffraction, and the characteristic peak in an atlas is shown as 8.8 degrees, 9.5 degrees, 10.2 degrees, 11.3 degrees, 12.0 degrees, 14.4 degrees, 16.8 degrees, 17.3 degrees, 20.6 degrees, 25.0 degrees, 27.8 degrees, 28.1 degrees and 30.2 degrees in a range of 20+/0.2 degrees. The pharmaceutical composition of the cefamandole nafate compound is a preparation and a pharmaceutical composition preparation containing the above cefamandole nafate compound and the preparation is powder-injection. The cefamandole nafate crystalline compound is high in stability and few in insoluble particles; a cosolvent is not needed, so that the compound can be directly and aseptically sub-packaged to obtain cefamandole nafate powder injection for injection. The cefamandole nafate crystalline compound is also fully mixed with aseptic sodium carbonate powder to be aseptically sub-packaged. The number of insoluble particles added with the powder injection of sodium carbonate is few on the basis of reaching standard request.

The invention discloses a method for preparation of fine cefamandole nafate, comprising the steps of mixing crude cefamandole nafate with organic sodium salt, salt-free water and organic solvent (1); controlling pH value of the reaction system to 5.5-7.5 and reaction temperature to 5-15 DEG C; adding active carbon and then filtering to obtain filtrate; mixing the filtrate with organic solvent (2) and separating out crystal to obtain the cefamandole nafate. The method for preparation of the fine cefamandole nafate provided by the invention overcomes the disadvantages of prior preparation method, and has the advantages of simple operation, short preparation period, easy quality control, good product stability and important application value.

The invention discloses a preparation process of cefamandole nafate. The preparation process comprises steps of: heating and stirring 7-amino cephalosporanic acid, 5-mercapto-1-methyltetrazole and a catalyst boron trifluoride acetonitrile complex for a reaction; and carrying out a cooling post-treatment to obtain cefditoren nuclear parent; conducting a heating reflux reaction on the cefditoren nuclear parent and a silanizing agent until the solution turns to a clarified state; adding N, N-dimethyl aniline under the protection of inert gas at a low temperature, dropwise adding D-(-)-O-formyl mandeloyl chloride for reaction, and carrying out post-treatment to obtain formyl cefamandole acid; and reacting the formyl cefamandole acid with an organic acid salt, and recrystallizing to obtain the cefamandole nafate. By the above way, the preparation process of cefamandole nafate provided by the invention employs a simple and easily implemented process to obtain high-yield cefditoren nuclear parent with low impurity content; dichloromethane is used as a solvent to obtain the cefamandole acid with greatly enhanced color grade and yield; and dosage of activated carbon in the post-treatment is obviously reduced, so as to reduce the production cost.

The invention provides a method for preparing a cefamandole nafate powder injection preparation. The method comprises the following steps: (a) performing a silanization reaction on 7-ACT and a silanization agent in a dichloromethane solvent under temperature control, and reducing the temperature after the reaction is completed so as to obtain a reaction liquid 1, wherein the solid-liquid ratio of7-ACT to dichloromethane is 1g:(3-6)ml; (b) dropwise adding (R)-(-)-O-formylmandeloyl chloride into the reaction liquid 1, controlling the temperature, performing an acylation reaction so as to obtaina reaction liquid 2; (c) performing treatment of extraction, decoloring and dehydration on the reaction liquid 2; (d) performing temperature control crystallization; and (e) washing a solid with acetone, drying, performing sterile sub-packaging, thereby obtaining the cefamandole nafate powder injection preparation. Due to adoption of a high-concentration dichloromethane reaction system, the method is rapid in silanization and acylation process, short in reaction time, low in reaction residue, high in product yield and small in impurity. After the reactions, organic solvents such as dichloromethane can be easily recycled and repeatedly used, so that the method is relatively environment-friendly, low in cost and applicable to large-scale industrial production.

The invention relates to a cefamandole nafate new crystal form and a crystallization preparing method thereof. The cefamandole nafate new crystal form is characterized by characterizing the characteristic peaks of a diffraction angle 2 theta degree and a DSC by using X-ray powder diffraction patterns, wherein the cefamandole nafate new crystal form is defined as VI. The preparing method comprises the following steps of adding the cefamandole nafate solid into the good solvent, and mixing at the temperature of 10-30 DEG C to enable the cefamandole nafate to dissolve completely, wherein the solution concentration is 0.05-0.4 g/ml; adding additives at different concentrations into the solution; adding a solventing-out agent into the solution, wherein the dosage of the solventing-out agent is 5-20 times the dosage of the good solvent; after cultivating the crystal, performing suction filtration on formed suspension liquid; drying to obtain a cefamandole nafate new crystal form product. The solubility of the new crystal form is improved by more than 5%; the new crystal form has higher solubility, so that the dissolution rate of a medicinal preparation can be improved. The traditional stable crystal form is of a needle shape, but the appearance of the new crystal form is of a prism shape, thus, the bulk density of products is improved by more than 8%, better mobility is realized, and accordingly convenience in package and transport of the products is improved.

The invention discloses a synthesis method for dextrorotation cefamandole nafate. The method includes the steps that in one-element organic solvent, 7-ACA and 1-methyl-1h-tetrazole-5-thiol are subjected to condensation with a boron trifluoride complex of the one-element organic solvent as a catalyst so as to generate 7-ATCA; and then, in another one-element organic solvent, under the effect of organic alkali, the 7-ATCA and S-(-)-formylmandeloyl chloride are made to react so as to generate the dextrorotation cefamandole nafate, then, an organic phase is left after hydrolysis and extraction phase splitting, organic acid sodium salt and another organic solvent indissolvable in dextrorotation cefamandole sodium are added, the dextrorotation cefamandole sodium is obtained through crystallization, finally, the dextrorotation cefamandole sodium is dissolved in water, organic solvent incapable of being dissolved in water is added together with organic or inorganic acid, an organic phase is left after extraction phase splitting, and reduced pressure rotary evaporation is conducted on the organic phase to obtain the dextrorotation cefamandole nafate. The method is simple, conditions are gentle, raw materials are easy to obtain, and purity of the finally-obtained product is 99% or above.

The invention discloses a 1/4 water and cefamandole nafate compound and a preparation method thereof. Each mole of cefamandole nafate contains 1/4 mole of water. The cefamandole nafate compound prepared by the method is low in impurity content, good in stability, good in mobility and low in hygroscopicity, and has a wider application prospect.

The invention relates to suspension powder injection of cefamandole nafate and a preparation method thereof and further relates to new application of the injection in treating acute suppurative cholangitis. The frozen-dried suspension powder injection comprises the following components in parts by weight: 1 part of cefamandole nafate, 1.5-12 parts of surfactant and 2-15 parts of frozen-dried supporting agents.

The invention discloses a preparation method of a Cefamandole Nafate powder injection for injection. The method includes the steps of: (1) strain preparation; (2) preparation and culture of seed tank; (3) preparation and culture of a fermentation tank; (4) filtration; (5) decolorization and concentration; (6) preparation of a reaction tank and pipeline; (7) preparation of enzyme catalytic reaction; (8) enzyme catalytic reaction; (9) crystallization; (10) centrifugation and vacuum drying; (11) preparation of 7-ATCA; (12) preparation of cefamandole acid; (13) preparation of Cefamandole Nafate; and (14) aseptic subpackaging, thus obtaining the Cefamandole Nafate powder injection for injection. The invention provides the method of improving the 7-ACA preparation process so as to improve the product quality of cefamandole.

The invention discloses a method for preparing a cefamandole nafate powder preparation for injection, wherein the method comprises the following steps: 1, dissolving N,N-dimethyl aniline; 2, dissolving D-formyl mandelic acid chloride; 3, carrying out a silylation reaction; 4, synthesizing cefamandole acid ester; 5, extracting; 6, carrying out dehydration and decolorization; 7, crystallizing; and 8, carrying out aseptic subpackaging. The reaction efficiency and the appearance quality of the product are improved by changing feeding and crystallization ways.

The invention relates to a cefamandole nafate medicine composition for treating bacterial infection and belongs to the technical field of medicines. The composition is composed of cefamandole nafate and sodium dihydrogen phosphate; cefamandole nafate is a crystal and an X-ray powder diffraction pattern obtained through measurement of Cu-K(alpha) ray is shown in the graph I. The novel crystal form of cefamandole provided by the invention is different from the crystal form structure in the prior art, through experimental verification, the fact that the novel crystal form compound is high in purity, good in mobility and stability, low in polymer content, low in hygroscopicity, and safe and reliable during clinical application is found, powder-injection prepared from the novel crystal form compound is good in stability, good in stability after being combined with a solvent, and extremely low in content of insoluble particles and is particularly suitable for being applied clinically.

The present invention discloses a cefamandole nafate composition for the treatment of infectious diseases and belongs to the technical field of medicine. The composition comprises cefamandole nafate and anhydrous sodium carbonate; the cefamandole nafate is a novel crystalline form compound; and an X-ray powder diffraction pattern obtained by Cu-K alpha radiation measurement is shown as a figure 1. The cefamandole nafate novel crystalline form provided by the invention differs from the crystal structure in the prior art; experiment verification is pleasantly surprised to find that the novelcrystalline compound has high purity, good liquidity, good stability, low polymer content and no hygroscopicity, and is safe and reliable for clinical applications; powder prepared from the novel crystalline form compound has good stability, good compatibility stability with the solvent and very low content of insoluble particles, and is very suitable for clinical application.

The invention relates to a cefamandole nafate new crystal form and a preparing method thereof. The cefamandole nafate new crystal form is characterized by characterizing the characteristic peaks of a diffraction angle 2 theta degree and a DSC by using X-ray powder diffraction patterns, wherein the new crystal form of the cefamandole nafate compound as V. The preparing method includes the following steps of adding the cefamandole nafate solid into the good solvent at the temperature of 10-30 DEG C, mixing to let the cefamandole nafate dissolve completely, wherein the solution concentration is 0.5 to 1.0 g/ml,; adding the poor solvent, and then reducing the system temperature to 0 to 5 DEG C; standing for cultivating the crystal for 4 to 72 hours; filtering, washing, and drying to obtain a cefamandole nafate new crystal form product. The melting range of the new crystal form is 160 to 180 DEG C, and the peak value is 169+/-2 DEG C which is higher than the melting points of crystal forms which are reported by all the other patents, thus the product thermal stability is improved. The purity, color, and the form of the new crystal form product are not changed after being stored for 100 days under room temperature and dry conditions, so that long time storage is favorably realized.

The invention provides a cefamandole nafate compound entity used for children. The structural formula is as shown in specifications. The cefamandole nafate compound entity is prepared through the following steps that step1, a cefamandole nafate crude product is dissolved in water, sodium hydrogen carbonate is added, pH is adjusted to 6.5-7.5, active carbon stirring and discoloring are performed, and then filtering is performed; step2, an extracting agent is added into filtrate, and then the filtrate is transferred into a pressure-resistant container in a filling mode and taken out after being defoamed and frozen in a temperature control mode; step3, an organic phase is removed, after a solid is melted, ethyl alcohol is dripped, and then slow stirring, crystal growing, filtration washing and vacuum drying are performed to obtain the cefamandole nafate finished product. The cefamandole nafate prepared through the method has the advantages of having few impurities, being high in purity and the like compared with a traditional technology.

The invention provides a cefamandole nafate refining method. The method comprises the steps of A, dissolving polyvinylpyrrolidone in a lower alcohol and water mixed solvent to prepare a polyvinylpyrrolidone solution of 0.1-1.0 mol/L, then adding a cefamandole nafate crude product, increasing temperature to 50-80 DEG C, adding activated carbon after complete dissolution, conducting stirring for 10-30 min, and then conducting filtration to obtain a filtrate for use; B, adding sodium iso-octoate of 15% to the filtration obtained in the step A dropwise, and regulating pH to 6.0-7.0, so that a cefamandole nafate crude product solution is obtained; C, adding acetone to the cefamandole nafate crude product solution obtained in the step B dropwise while stirring, then conducting ultrasonic treatment for 10-30 min, continuing to add acetone, conducting stirring at indoor temperature for 1-2 h to enable a large number of crystals to be separated out, conducting filtration, conducting washing with a small amount of ethyl alcohol, and conducting vacuum drying so that a cefamandole nafate refined product can be obtained, wherein the amount of acetone added at the second time is 0.8-1.2 times that of acetone added at the first time. The refining method has the advantages that yield and purity are high, and the product is high in stability and light in color.

The invention discloses a detection method of formic acid in cefamandole nafate. According to the method, a liquid chromatography is used for detecting; and a mobile phase used in a detection process is a phosphoric acid water solution with the volume concentration of 0.02%-0.1%. By taking the phosphoric acid water solution with the volume concentration of 0.02%-0.1% as the mobile phase for detecting the formic acid in the cefamandole nafate in a liquid chromatography, the dissociation of the formic acid can be effectively inhibited, and retention time and separation degree of the formic acid can be improved very well, so that the separation degrees of the formic acid and front and back adjacent impurity peaks are 3.68 and 1.78 respectively; and the blocking of a chromatographic column is not caused. Furthermore, the method has high accuracy and precision and good stability, and is easy to realize in industrialization.